Extended-Release niacin raises fasting glucose levels

March 28, 2012
Extended-Release niacin raises fasting glucose levels

(HealthDay) -- The combination of extended-release niacin (N) with ezetimibe plus simvastatin (E/S) to treat hyperlipidemia is associated with increased fasting glucose (FG) levels compared with E/S alone, but these cases tend to be transient and remit without intervention, according to research published in the April issue of Diabetes Care.

In an effort to determine whether extended-release niacin affected FG levels or the incidence of new-onset diabetes, John R. Guyton, M.D., of Duke University in Durham, N.C., and colleagues conducted a secondary analysis of data from 942 patients with hyperlipidemia treated for 64 weeks with either E/S or E/S plus extended-release niacin (E/S+N).

The researchers found that FG levels peaked by eight to 12 weeks and then declined even without use of antidiabetic therapies. At 64 weeks, the criteria for new onset diabetes was met by 3.5 percent of those taking E/S+N and 2.6 percent of those taking E/S (P = 0.66). The criteria for diabetes was transiently met by an additional 1.4 percent of those taking E/S+N versus 0.4 percent taking E/S, all of whom then remitted (P = 0.46). By 24 weeks, 25 of the 28 new diabetes diagnoses in the E/S+N group had occurred. In those with diabetes at baseline, antidiabetic treatment modification was undertaken by 13.9 percent of those taking E/S+N versus 11.6 percent taking E/S.

"In summary, combination E/S+N produced small initial increases in FG and new diagnoses of diabetes that dissipated over time, largely without the use of antidiabetic medication," the authors write.

The study was funded by Merck/Schering-Plough Pharmaceuticals; several authors disclosed to pharmaceutical companies, including Merck.

Explore further: Dapagliflozin aids glycemic control in type 2 diabetes

More information: Abstract
Full Text (subscription or payment may be required)

Related Stories

Dapagliflozin aids glycemic control in type 2 diabetes

March 20, 2012
(HealthDay) -- For patients with inadequately controlled type 2 diabetes, treatment with dapagliflozin is associated with improved glycemic control, stabilized insulin dosing, and weight reductions, according to research ...

Combo of diabetes, depression increases post-MI mortality

February 27, 2012
(HealthDay) -- Having both diabetes and depression significantly increases the risk of dying in the years following a heart attack, beyond the increased risk from either condition alone, according to a study published in ...

Diabetes associated with higher risk of cardiovascular problems in men

March 25, 2012
According to a new study by researchers at Brigham and Women's Hospital (BWH), men with type 2 diabetes treated with insulin without a history of cardiovascular disease (CVD) were at higher risk for major cardiovascular events ...

FDA approves first diabetes-cholesterol combo pill

October 7, 2011
(AP) -- The first combination pill for the millions of people with the dangerous combination of diabetes and high cholesterol won U.S. approval Friday, offering convenience - and savings - to patients taking multiple pills.

Recommended for you

Genetic discovery may help better identify children at risk for type 1 diabetes

January 17, 2018
Six novel chromosomal regions identified by scientists leading a large, prospective study of children at risk for type 1 diabetes will enable the discovery of more genes that cause the disease and more targets for treating ...

Women who have gestational diabetes in pregnancy are at higher risk of future health issues

January 16, 2018
Women who have gestational diabetes mellitus (GDM) during pregnancy have a higher than usual risk of developing type 2 diabetes, hypertension, and ischemic heart disease in the future, according to new research led by the ...

Diabetes gene found that causes low and high blood sugar levels in the same family

January 15, 2018
A study of families with rare blood sugar conditions has revealed a new gene thought to be critical in the regulation of insulin, the key hormone in diabetes.

Discovery could lead to new therapies for diabetics

January 12, 2018
New research by MDI Biological Laboratory scientist Sandra Rieger, Ph.D., and her team has demonstrated that an enzyme she had previously identified as playing a role in peripheral neuropathy induced by cancer chemotherapy ...

Enzyme shown to regulate inflammation and metabolism in fat tissue

January 11, 2018
The human body has two primary kinds of fat—white fat, which stores excess calories and is associated with obesity, and brown fat, which burns calories in order to produce heat and has garnered interest as a potential means ...

Big strides made in diabetes care

January 5, 2018
(HealthDay)—This past year was a busy, productive one for diabetes research and care.

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.